Etesevimab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Etesevimab
Accession Number
DB15897
Description

Etesevimab (LY-CoV016, also known as JS016) is a fully human and recombinant monoclonal antibody that targets the SARS-CoV-2 surface spike protein receptor binding domain.1,2

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Etesevimab
External IDs
  • CB6
  • JS016
  • LY-3832479
  • LY-CoV016
  • LY3832479
  • NP005
  • WHO 11873

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication
Not Available
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics
Not Available
Mechanism of action

Etesevimab aims to neutralize SARS-CoV-2 by specifically binding to the virus' surface spike protein receptor binding domain. This high affinity binding then prevents SARS-CoV-2 from binding to the ACE2 host cell surface receptor. Etesevimab is currently being investigated against COVID-19.

TargetActionsOrganism
ASpike glycoprotein
binder
SARS-CoV-2
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
EtesevimabInjection, solution35 mg/1mLIntravenousEli Lilly and Company2021-02-09Not applicableUS flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
EtesevimabEtesevimab (35 mg/1mL)Injection, solutionIntravenousEli Lilly and Company2021-02-09Not applicableUS flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Chemical Identifiers

UNII
N7Q9NLF11I
CAS number
2423948-94-9

References

General References
  1. Lilly Investors: Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs [Link]
  2. Junshi Biosciences: Junshi Biosciences Announces Completion of Enrollment in Phase I Trial of JS016 [Link]
RxNav
2477854

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3RecruitingPreventionCoronavirus Disease 2019 (COVID‑19)1
2RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19)1
2, 3RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19)1
1CompletedBasic ScienceHealthy Volunteers2
1RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / COVID-19; and High Infection Risk of SARS-CoV-21
Not AvailableNot Yet RecruitingNot AvailableCoronavirus Disease 2019 (COVID‑19)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solutionIntravenous35 mg/1mL
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Targets

Drugtargets
Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Learn more
Accelerate your drug discovery research with our ADMET & drug target dataset
Learn more
Kind
Protein
Organism
SARS-CoV-2
Pharmacological action
Yes
Actions
Binder
General Function
Spike protein S1 attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. Binding to human ACE2 receptor and internalization of the virus into the endosomes of the host cell induces conformational changes in the Spike glycoprotein (PubMed:32142651, PubMed:32075877, PubMed:32155444). Uses also human TMPRSS2 for priming in human lung cells which is an essential step for viral entry (PubMed:32142651). Can be alternatively processed by host furin (PubMed:32362314). Proteolysis by cathepsin CTSL may unmask the fusion peptide of S2 and activate membranes fusion within endosomes.
Specific Function
Host cell surface receptor binding
Gene Name
S
Uniprot ID
P0DTC2
Uniprot Name
Spike glycoprotein
Molecular Weight
141177.29 Da
References
  1. Lilly Investors: Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs [Link]
  2. Junshi Biosciences: Junshi Biosciences Announces Completion of Enrollment in Phase I Trial of JS016 [Link]

Drug created on October 07, 2020 16:21 / Updated on March 04, 2021 09:26